INAGAKI Nobuya

Last updated: Aug 7, 2016 at 23:39

Name	INAGAKI Nobuya
Affiliation	Kyoto University
Section	Graduate School of Medicine, Graduate School of Medicine Medicine
Job title	Professor,Professor,Professor
Degree	Doctor of Medical Science

Research Interests

Medicochirurgic(1) , Diabetes and Clinical Nutrition(1) , Nutriology(1) , physiology(218)

Research Areas

Basic medicine / General physiology /
Basic medicine / General medical chemistry /
Clinical internal medicine / Metabolomics /

Academic & Professional Experience

Plain Text1 2 >

1992

1995

Instructer,

Chiba University School of Medicine

1995

1996

Lecturer,

Chiba University School of Medicine

1996

1997

Associate Professor,

Education

Plain Text

1992

Graduate School, Division of Medicine, Kyoto University

1984

Faculty of Medicine, Kyoto University

Committee Memberships

Plain Text

The Physiological Society of Japan Councilor

The Japanese Biochemical Society Administration officer

The Japan Diabetes Society Councilor

Awards & Honors

Plain Text

1997

The Lilly Award (Japan Diabetes association)

Published Papers

Plain Text1 2 3 >

Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.

Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, Kakiuchi H, Sato Y, Sakai S, Samukawa Y.

Clin Ther 38(1) 66-88 2016 [Refereed]

Insulin Secretory Defect and Insulin Resistance in Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance.

Aoyama-Sasabe S, Fukushima M, Xin X, Taniguchi A, Nakai Y, Mitsui R, Takahashi Y, Tsuji H, Yabe D, Yasuda K, Kurose T, Inagaki N, Seino Y.

J Diabetes Res. 2016 [Refereed]

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.

Kondo Y, Harada N, Hamasaki A, Kaneko S, Yasuda K, Ogawa E, Harashima S, Yoneda H, Fujita Y, Kitano N, Nakamura Y, Matsuo F, Shinji M, Hinotsu S, Nakayama T, Inagaki N; MAIKO Study group.

Diabetol Metab Syndr 8 15 2016 [Refereed]

Impaired adipogenic capacity in induced pluripotent stem cells from lipodystrophic patients with BSCL2 mutations.

Mori E, Fujikura J, Noguchi M, Nakao K, Matsubara M, Sone M, Taura D, Kusakabe T, Ebihara K, Tanaka T, Hosoda K, Takahashi K, Asaka I, Inagaki N, Nakao K.

Metabolism 65(4) 543-556 2016 [Refereed]

Brain-specific natriuretic peptide receptor-B deletion attenuates high-fat diet-induced visceral and hepatic lipid deposition in mice.

Yamashita Y, Yamada-Goto N, Katsuura G, Ochi Y, Kanai Y, Miyazaki Y, Kuwahara K, Kanamoto N, Miura M, Yasoda A, Ohinata K, Inagaki N, Nakao K.

Peptides 81 38-50 2016 [Refereed]

Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.

Sakai S, Kaku K, Seino Y, Inagaki N, Haneda M, Sasaki T, Fukatsu A, Kakiuchi H, Samukawa Y

Clin Ther 38(4) 843-862 2016 [Refereed]

Src regulates insulin secretion and glucose metabolism by influencing subcellular localization of glucokinase in pancreatic β-cells.

Sato H, Nagashima K, Ogura M, Sato Y, Tahara Y, Ogura K, Yamano G, Sugizaki K, Fujita N, Tatsuoka H, Usui R, Mukai E, Fujimoto S, Inagaki N

J Diabetes Investig 7(2) 171-178 2016 [Refereed]

Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study.

Inagaki N, Sano H, Seki Y, Kuroda S, Kaku K.

J Diabetes Investig 2016 [Refereed]

Cluster-randomized trial to improve the quality of diabetes management: The study for the efficacy assessment of the standard diabetes manual (SEAS-DM).

Noto H, Tanizawa Y, Aizawa T, Sone H, Yoshioka N, Terauchi Y, Inagaki N, Noda M.

J Diabetes Investig 7(4) 539-543 2016 [Refereed]

Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy.

Ueda-Sakane Y, Kanamoto N, Fushimi Y, Tanaka-Mizuno S, Yasuno S, Miura M, Sone M, Yasoda A, Okada T, Togashi K, Nakao K, Inagaki N.

Endocr J 2016 [Refereed]

Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults.

Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Hammad A, Tamai Y, Inagaki N, Uemoto S.

Nutrition S0899-9007(16) 30043 2016 [Refereed]

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.

Inagaki N, Harashima S, Maruyama N, Kawaguchi Y, Goda M, Iijima H.

Cardiovasc Diabetol 15 89 2016 [Refereed]

Nardilysin is Required for maintaining Pancreatic β-Cell Function.

Nishi K, Sato Y, Ohno M, Hiraoka Y, Saijo S, Sakamoto J, Chen PM, Morita Y, Matsuda S, Iwasaki K, Sugizaki K, Harada N, Mukumoto Y, Kiyonari H, Furuyama K, Kawaguchi Y, Uemoto S, Kita T, Inagaki N, Kimura T, Nishi E.

Diabetes. 2016 [Refereed]

Adiposity induced by interleukin-17A blockade.

Nakamura T, Iwasaki Y, Yamane S, Ogura M, Yasoda A, Nagashima K, Inagaki N.

Diabetes Metab S1262-3636(16) 30441-30444 2016 [Refereed]

The combination of dulaglutide and biguanide reduced body weight in Japanese patients with type 2 diabetes.

Inagaki N, Araki E, Oura T, Matsui A, Takeuchi M, Tanizawa Y.

Diabetes Obes Metab. 2016 [Refereed]

A comparison between 11C-methionine PET/CT and MIBI SPECT/CT for localization of parathyroid adenomas/hyperplasia.

Hayakawa N, Nakamoto Y, Kurihara K, Yasoda A, Kanamoto N, Miura M, Inagaki N, Togashi K.

Nucl Med Commun 36(1) 53-59 2015 [Refereed]

Free fatty acid receptor GPR120 is highly expressed in enteroendocrine K cells of the upper small intestine and has a critical role in GIP secretion after fat ingestion.

Iwasaki K, Harada N, Sasaki K, Yamane S, Iida K, Suzuki K, Hamasaki A, Nasteska D, Shibue K, Joo E, Harada T, Hashimoto T, Asakawa Y, Hirasawa A, Inagaki N.

Endocrinology. 156(3) 837-846 2015 [Refereed]

Glycemic variability is associated with quality of life and treatment satisfaction in patients with type 1 diabetes.

Ayano-Takahara S, Ikeda K, Fujimoto S, Hamasaki A, Harashima S, Toyoda K, Fujita Y, Nagashima K, Tanaka D, Inagaki N.

Diabetes Care. 38(1) e1-e2 2015 [Refereed]

Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.

Inagaki N, Onouchi H, Maezawa H, Kuroda S, Kaku K.

Lancet Diabetes Endocrinol 3(3) 191-197 2015 [Refereed]

Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients.

Yabe D, Kuroe A, Watanabe K, Iwasaki M, Hamasaki A, Hamamoto Y, Harada N, Yamane S, Lee S, Murotani K, Deacon CF, Holst JJ, Hirano T, Inagaki N, Kurose T, Seino Y.

J Diabetes Complications 29(3) 413-421 2015 [Refereed]

Importance of contralateral aldosterone suppression during adrenal vein sampling in the subtype evaluation of primary aldosteronism.

Umakoshi H, Tanase-Nakao K, Wada N, Ichijo T, Sone M, Inagaki N, Katabami T, Kamemura K, Matsuda Y, Fujii Y, Kai T, Fukuoka T, Sakamoto R, Ogo A, Suzuki T, Tsuiki M, Shimatsu A, Naruse M.

Clin Endocrinol (Oxf). 83(4) 462-467 2015 [Refereed]

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.

Inagaki N, Kondo K, Yoshinari T, Kuki H.

J Diabetes Investig. 6(2) 210-218 2015 [Refereed]

Obara A, Fujita Y, Abudukadier A, Fukushima T, Oguri Y, Ogura M, Harashima S, Hosokawa M, Inagaki N.

Biochem Biophys Res Commun 460(4) 1047-1052 2015 [Refereed]

Increased Bone Turnover and Possible Accelerated Fracture Healing in a Murine Model With an Increased Circulating C-Type Natriuretic Peptide.

Kondo E, Yasoda A, Fujii T, Nakao K, Yamashita Y, Ueda-Sakane Y, Kanamoto N, Miura M, Arai H, Mukoyama M, Inagaki N, Nakao K.

Endocrinology. 156(7) 2518-2529 2015 [Refereed]

Enteral supplementation with glutamine, fiber, and oligosaccharide modulates incretin and glucagon-like peptide-2 secretion.

Joo E, Muraoka A, Hamasaki A, Harada N, Yamane S, Kondo Y, Suzuki K, Nasteska D, Shibue K, Harada T, Iwasaki K, Tsuji H, Shide K, Inagaki N.

J Diabetes Investig. 6(3) 302-308 2015 [Refereed]

Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia.

Choudhary P, Rickels MR, Senior PA, Vantyghem MC, Maffi P, Kay TW, Keymeulen B, Inagaki N, Saudek F, Lehmann R, Hering BJ.

Diabetes Care. 38(6) 1016-1029 2015 [Refereed]

Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.

Seino Y, Ikeda Y, Niemoeller E, Watanabe D, Takagi H, Yabe D, Inagaki N.

Horm Metab Res 47(12) 895-900 2015 [Refereed]

Paternal allelic mutation at the Kcnq1 locus reduces pancreatic β-cell mass by epigenetic modification of Cdkn1c.

Asahara S, Etoh H, Inoue H, Teruyama K, Shibutani Y, Ihara Y, Kawada Y, Bartolome A, Hashimoto N, Matsuda T, Koyanagi-Kimura M, Kanno A, Hirota Y, Hosooka T, Nagashima K, Nishimura W, Inoue H, Matsumoto M, Higgins MJ, Yasuda K, Inagaki N, Seino S, Kasuga M, Kido Y.

Proc Natl Acad Sci U S A. 112(27) 8332-8337 2015 [Refereed]

Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study.

Inagaki N, Goda M, Yokota S, Maruyama N, Iijima H.

Expert Opin Pharmacother. 16(11) 1577-1591 2015 [Refereed]

Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.

Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T.

Diabetes Obes Metab. 17(10) 994-1002 2015 [Refereed]

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.

Seino Y, Inagaki N, Haneda M, Kaku K, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

J Diabetes Investig 6(4) 443-453 2015 [Refereed]

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.

Iijima H, Kifuji T, Maruyama N, Inagaki N.

Adv Ther. 32(8) 768-782 2015 [Refereed]

Effect of nutritional counseling and long term isomaltulose based liquid formula (MHN-01) intake on metabolic syndrome.

Takeda E, Yamanaka-Okumura H, Taketani Y, Inagaki N, Hosokawa M, Shide K, Maegawa H, Kondo K, Kawasaki E, Shinozaki S, Fujinaka Y, Matsubara T, Katayama T, Sasaki H, Kawashima A, Aonuma H.

J Clin Biochem Nutr. 57(2) 140-144 2015 [Refereed]

Fructose induces glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and insulin secretion: Role of adenosine triphosphate-sensitive K(+) channels.

Seino Y, Ogata H, Maekawa R, Izumoto T, Iida A, Harada N, Miki T, Seino S, Inagaki N, Tsunekawa S, Oiso Y, Hamada Y.

J Diabetes Investig 6(5) 522-526 2015 [Refereed]

Once Daily Self-Monitoring of Blood Glucose (SMBG) Improves Glycemic Control in Oral Hypoglycemic Agents (OHA)-Treated Diabetes: SMBG-OHA Follow-Up Study.

Harashima S, Nishimura A, Ikeda K, Wang Y, Liu Y, Inagaki N.

J Diabetes Sci Technol. 10(2) 378-382 2015 [Refereed]

Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.

Inagaki N, Goda M, Yokota S, Maruyama N, Iijima H.

Adv Ther. 32(11) 1085-1103 2015 [Refereed]

Carbohydrate intake is associated with time spent in the euglycemic range in patients with type 1 diabetes.

Ayano-Takahara S, Ikeda K, Fujimoto S, Asai K, Oguri Y, Harashima S, Tsuji H, Shide K, Inagaki N.

J Diabetes Investig 6(6) 678-686 2015 [Refereed]

KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state.

Ogata H, Seino Y, Harada N, Iida A, Suzuki K, Izumoto T, Ishikawa K, Uenishi E, Ozaki N, Hayashi Y, Miki T, Inagaki N, Tsunekawa S, Hamada Y, Seino S, Oiso Y.

J Endocrinol 222(2) 191-200 2014 [Refereed]

Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.

Sakai T, Kusakabe T, Ebihara K, Aotani D, Yamamoto-Kataoka S, Zhao M, Gumbilai VM, Ebihara C, Aizawa-Abe M, Yamamoto Y, Noguchi M, Fujikura J, Hosoda K, Inagaki N, Nakao K.

Am J Physiol Endocrinol Metab. 307(8) E712-E719 2014 [Refereed]

Restless legs syndrome in patients with type 2 diabetes: effectiveness of pramipexole therapy.

Harashima S, Nishimura A, Osugi T, Wang Y, Liu Y, Takayama H, Inagaki N.

BMJ Support Palliat Care. 6(1) 89-93 2014 [Refereed]

Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry.

Inagaki N, Ueki K, Tanizawa Y, Watada H, Nakamura J, Yamada Y, Shimomura I, Nishimura R, Yamazaki T, Kadowaki T.

BMJ Open 4(9) 2014 [Refereed]

Enhanced vascular endothelial growth factor signaling in islets contributes to β cell injury and consequential diabetes in spontaneously diabetic Torii rats.

Mukai E, Ohta T, Kawamura H, Lee EY, Morita A, Sasase T, Miyajima K, Inagaki N, Iwanaga T, Miki T.

Diabetes Res Clin Pract 106(2) 303-311 2014 [Refereed]

Social orientation and diabetes-related distress in Japanese and American patients with type 2 diabetes.

Ikeda K, Fujimoto S, Morling B, Ayano-Takahara S, Carroll AE, Harashima S, Uchida Y, Inagaki N.

PLoS One 9(10) 2014 [Refereed]

Glutamate acts as a key signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion.

Gheni G, Ogura M, Iwasaki M, Yokoi N, Minami K, Nakayama Y, Harada K, Hastoy B, Wu X, Takahashi H, Kimura K, Matsubara T, Hoshikawa R, Hatano N, Sugawara K, Shibasaki T, Inagaki N, Bamba T, Mizoguchi A, Fukusaki E, Rorsman P, Seino S.

Cell Rep. 9(2) 661-673 2014 [Refereed]

Relationship and factors responsible for regulating fasting and post-challenge plasma glucose levels in the early stage development of type 2 diabetes mellitus.

Aoyama-Sasabe S, Xin X, Taniguchi A, Nakai Y, Mitsui R, Tsuji H, Yabe D, Yasuda K, Kurose T, Inagaki N, Seino Y, Fukushima M.

J Diabetes Investig. 5(6) 663-670 2014 [Refereed]

Fatty acid-binding protein 5 regulates diet-induced obesity via GIP secretion from enteroendocrine K cells in response to fat ingestion.

Shibue K, Yamane S, Harada N, Hamasaki A, Suzuki K, Joo E, Iwasaki K, Nasteska D, Harada T, Hayashi Y, Adachi Y, Owada Y, Takayanagi R, Inagaki N.

Am J Physiol Endocrinol Metab. 308(7) E583-E591 2014 [Refereed]

SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: A phase 2, randomised, double-blind, placebo-controlled trial

N. Inagaki; H. Onouchi; H. Sano; N. Funao; S. Kuroda; K. Kaku

The Lancet Diabetes and Endocrinology 2(2) 125-132 2014 [Refereed]

Long-term effect of dipeptidyl peptidase-4 inhibition on β-cell mass in an advanced-aged diet-induced obesity mouse model

S. Yamane; N. Inagaki

Journal of Diabetes Investigation 5(2) 142-143 2014 [Refereed]

Palmitate induces reactive oxygen species production and β-cell dysfunction by activating nicotinamide adenine dinucleotide phosphate oxidase through Src signaling

Y. Sato; S. Fujimoto; E. Mukai; H. Sato; Y. Tahara; K. Ogura; G. Yamano; M. Ogura; K. Nagashima; N. Inagaki

Journal of Diabetes Investigation 5(1) 19-26 2014 [Refereed]

A new equation to estimate basal energy expenditure of patients with diabetes

K. Ikeda; S. Fujimoto; M. Goto; C. Yamada; A. Hamasaki; M. Ida; K. Nagashima; K. Shide; T. Kawamura; N. Inagaki

Clinical Nutrition 32(5) 777-782 Oct 2013 [Refereed]

Reduction of reactive oxygen species ameliorates metabolism-secretion coupling in islets of diabetic GK rats by suppressing lactate overproduction

M. Sasaki; S. Fujimoto; Y. Sato; Y. Nishi; E. Mukai; G. Yamano; H. Sato; Y. Tahara; K. Ogura; K. Nagashima; N. Inagaki

Diabetes 62(6) 1996-2003 Jun 2013 [Refereed]

Exome sequencing identifies a new candidate mutation for susceptibility to diabetes in a family with highly aggregated type 2 diabetes

D. Tanaka; K. Nagashima; M. Sasaki; S. Funakoshi; Y. Kondo; K. Yasuda; A. Koizumi; N. Inagaki

Molecular Genetics and Metabolism 109(1) 112-117 May 2013 [Refereed]

Clinical and functional characterization of the pro1198Leu ABCC8 gene mutation associated with permanent neonatal diabetes mellitus

T. Takagi; H. Furuta; M. Miyawaki; K. Nagashima; T. Shimada; A. Doi; S. Matsuno; D. Tanaka; M. Nishi; H. Sasaki; N. Inagaki; N. Yoshikawa; K. Nanjo; T. Akamizu

Journal of Diabetes Investigation 4(3) 269-273 May 2013 [Refereed]

Enteral supplement enriched with glutamine, fiber, and oligosaccharide attenuates experimental colitis in mice

E. Joo; S. Yamane; A. Hamasaki; N. Harada; T. Matsunaga; A. Muraoka; K. Suzuki; D. Nasteska; T. Fukushima; T. Hayashi; H. Tsuji; K. Shide; K. Tsuda; N. Inagaki

Nutrition 29(3) 549-555 Mar 2013 [Refereed]

Self-monitoring of blood glucose (SMBG) improves glycaemic control in oral hypoglycaemic agent (OHA)-treated type 2 diabetes (SMBG-OHA study)

S.-I. Harashima; T. Fukushima; M. Sasaki; Y. Nishi; S. Fujimoto; M. Ogura; S. Yamane; D. Tanaka; N. Harada; A. Hamasaki; K. Nagashima; Y. Nakahigashi; Y. Seino; N. Inagaki

Diabetes/Metabolism Research and Reviews 29(1) 77-84 Jan 2013 [Refereed]

Development of novel cell lines of diabetic dysfunction model fit for cell-based screening tests of medicinal materials

M. Saito; A. Hayakawa; N. Inagaki; H. Matsuoka

Cytotechnology 65(1) 105-118 2013 [Refereed]

Transcriptional regulatory factor X6 (RFX6) increases gastric inhibitory polypeptide (GIP) expression in enteroendocrine k-cells and is involved in GIP hypersecretion in high fat diet-induced obesity

K. Suzuki; N. Harada; S. Yamane; Y. Nakamura; K. Sasaki; D. Nasteska; E. Joo; K. Shibue; T. Harada; A. Hamasaki; K. Toyoda; K. Nagashima; N. Inagaki

Journal of Biological Chemistry 288(3) 1929-1938 2013 [Refereed]

Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes

E. Araki; R. Kawamori; N. Inagaki; H. Watada; N. Hayashi; Y. Horie; A. Sarashina; S. Thiemann; M. von Eynatten; K. Dugi; H.-J. Woerle

Diabetes, Obesity and Metabolism 15(4) 364-371 2013 [Refereed]

Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients

S.-I. Harashima; D. Tanaka; S. Yamane; M. Ogura; Y. Fujita; Y. Murata; M. Seike; T. Koizumi; M. Aono; Y. Wang; N. Inagaki

Hormone and Metabolic Research 45(3) 231-238 2013 [Refereed]

A patient who developed symptomatic reactive hypoglycemia 14 years after total gastrectomy and was successfully treated with miglitol

Y. Kondo; K. Toyoda; T. Santo; J. Fujii; M. Fukushima; N. Inagaki; K. Yasuda

Diabetology International 4(1) 66-70 2013 [Refereed]

Intracellular ATP-binding cassette transporter A3 is expressed in lung cancer cells and modulates susceptibility to cisplatin and paclitaxel

T.R. Overbeck; T. Hupfeld; D. Krause; R. Waldmann-Beushausen; B. Chapuy; B. Güldenzoph; T. Aung; N. Inagaki; F.A. Schöndube; B.C. Danner; L. Truemper; G.G. Wulf

Oncology (Switzerland) 84(6) 362-370 2013 [Refereed]

Mastication and Risk for Diabetes in a Japanese Population: A Cross-Sectional Study

T. Yamazaki; M. Yamori; K. Asai; I. Nakano-Araki; A. Yamaguchi; K. Takahashi; A. Sekine; F. Matsuda; S. Kosugi; T. Nakayama; N. Inagaki; K. Bessho

PLoS ONE 8(6) 2013 [Refereed]

Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1year in Japanese patients with type 2 diabetes

N. Inagaki; H. Watada; M. Murai; T. Kagimura; Y. Gong; S. Patel; H.-J. Woerle

Diabetes, Obesity and Metabolism 15(9) 833-843 2013 [Refereed]

A hospital-based cross-sectional study to develop an estimation formula for 2-h post-challenge plasma glucose for screening impaired glucose tolerance

Y. Kondo; N. Harada; T. Sozu; A. Hamasaki; S. Yamane; A. Muraoka; T. Harada; K. Shibue; D. Nasteska; E. Joo; K. Sasaki; N. Inagaki

Diabetes Research and Clinical Practice 101(2) 218-225 2013 [Refereed]

Lack of goal attainment regarding the low-density lipoprotein cholesterol level in the management of type 2 diabetes mellitus

M. Hosokawa; A. Hamasaki; K. Nagashima; S. Harashima; K. Toyoda; Y. Fujita; N. Harada; Y. Nakahigashi; S. Fujimoto; N. Inagaki

Internal Medicine 52(21) 2409-2415 2013 [Refereed]

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, 12-week study

N. Inagaki; K. Kondo; T. Yoshinari; N. Maruyama; Y. Susuta; H. Kuki

Diabetes, Obesity and Metabolism 15(12) 1136-1145 2013 [Refereed]

Tetrahydrobiopterin has a glucose-lowering effect by suppressing hepatic gluconeogenesis in an endothelial nitric oxide synthase dependent manner in diabetic mice

A. Abudukadier; Y. Fujita; A. Obara; A. Ohashi; T. Fukushima; Y. Sato; M. Ogura; Y. Nakamura; S. Fujimoto; M. Hosokawa; H. Hasegawa; N. Inagaki

Diabetes 62(9) 3033-3043 2013 [Refereed]

[Case report; a case of gastorinoma with subclinical insulinoma presenting repeated episodes of hypoglycemic attack].

K. Shibue; S. Harashima; Y. Nakamoto; A. Hamasaki; N. Inagaki

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 102(7) 1794-1796 2013 [Refereed]

A Case of Type 1 Diabetes Mellitus Associated with Ketoacidosis Triggered by a Rapid Reduction of the Dose of Insulin with the Administration of a Very-low-carbohydrate Diet

T. Fukushima; A. Hamasaki; K. Asai; M. Sasaki; K. Shibue; M. Kanno; K. Shide; K. Nagashima; N. Inagaki

Journal of the Japan Diabetes Society 56(9) 653-659 2013 [Refereed]

Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children

F. Flamein; L. Riffault; C. Muselet-charlier; J. Pernelle; D. Feldmann; L. Jonard; A. Durand-schneider; A. Coulomb; M. Maurice; L.M. Nogee; N. Inagaki; S. Amselem; J.C. Dubus; V. Rigourd; F. Brémont; C. Marguet; J. Brouard; J. De blic; A. Clement; R. Epaud; L. Guillot

Human Molecular Genetics 21(4) 765-775 2012 [Refereed]

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes

D. Yabe; K. Watanabe; K. Sugawara; H. Kuwata; Y. Kitamoto; K. Sugizaki; S. Fujiwara; M. Hishizawa; T. Hyo; K. Kuwabara; K. Yokota; M. Iwasaki; N. Kitatani; T. Kurose; N. Inagaki; Y. Seino

Journal of Diabetes Investigation 3(1) 70-79 2012 [Refereed]

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: A randomized, placebo and active comparator-controlled, double-blind study

R. Kawamori; N. Inagaki; E. Araki; H. Watada; N. Hayashi; Y. Horie; A. Sarashina; Y. Gong; M. von Eynatten; H.J. Woerle; K.A. Dugi

Diabetes, Obesity and Metabolism 14(4) 348-357 2012 [Refereed]

Sitagliptin add-on to low dosage sulphonylureas: Efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes

S.-I. Harashima; M. Ogura; D. Tanaka; T. Fukushima; Y. Wang; T. Koizumi; M. Aono; Y. Murata; M. Seike; N. Inagaki

International Journal of Clinical Practice 66(5) 465-476 2012 [Refereed]

Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis

K. Toyama; A. Yonezawa; S. Masuda; R. Osawa; M. Hosokawa; S. Fujimoto; N. Inagaki; K. Inui; T. Katsura

British Journal of Pharmacology 166(3) 1183-1191 2012 [Refereed]

Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance

S. Yamane; N. Harada; A. Hamasaki; A. Muraoka; E. Joo; K. Suzuki; D. Nasteska; D. Tanaka; M. Ogura; S.-I. Harashima; N. Inagaki

Journal of Diabetes Investigation 3(1) 80-85 2012 [Refereed]

Sorting nexin 19 regulates the number of dense core vesicles in pancreatic β-cells

S.-I. Harashima; T. Horiuchi; Y. Wang; A.L. Notkins; Y. Seino; N. Inagaki

Journal of Diabetes Investigation 3(1) 52-61 2012 [Refereed]

Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese

R. Mitsui; M. Fukushima; A. Taniguchi; Y. Nakai; S. Aoyama; Y. Takahashi; H. Tsuji; D. Yabe; K. Yasuda; T. Kurose; T. Kawakita; Y. Seino; N. Inagaki

Journal of Diabetes Investigation 3(4) 377-383 2012 [Refereed]

Role of sodium-glucose transporters in glucose uptake of the intestine and kidney

N. Harada; N. Inagaki

Journal of Diabetes Investigation 3(4) 352-353 2012 [Refereed]

Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferio

N. Inagaki; Y. Atsumi; T. Oura; H. Saito; T. Imaoka

Clinical Therapeutics 34(9) 1892-1908.e1 2012 [Refereed]

Ingestion of a moderate high-sucrose diet results in glucose intolerance with reduced liver glucokinase activity and impaired glucagon-like peptide-1 secretion

E. Sakamoto; Y. Seino; A. Fukami; N. Mizutani; S. Tsunekawa; K. Ishikawa; H. Ogata; E. Uenishi; H. Kamiya; Y. Hamada; H. Sato; N. Harada; Y. Toyoda; I. Miwa; J. Nakamura; N. Inagaki; Y. Oiso; N. Ozaki

Journal of Diabetes Investigation 3(5) 432-440 2012 [Refereed]

SIRT5 deacetylates and activates urate oxidase in liver mitochondria of mice

Y. Nakamura; M. Ogura; K. Ogura; D. Tanaka; N. Inagaki

FEBS Letters 586(23) 4076-4081 2012 [Refereed]

BK Channels Reveal Novel Phosphate Sensitivity in SNr Neurons

J.J. Ji; L. Chen; X. Duan; X. Song; W. Su; P. Zhang; L. Li; S. Bai; Y. Sun; N. Inagaki

PLoS ONE 7(12) 2012 [Refereed]

ABCA17 mediates sterol efflux from mouse spermatozoa plasma membranes

C.R. Morales; X. Ni; C.E. Smith; N. Inagaki; L. Hermo

Histology and Histopathology 27(3) 317-328 2012 [Refereed]

[Clinical biomarkers for diabetes mellitus].

S. Yamane; N. Inagaki

Nihon rinsho. Japanese journal of clinical medicine 70(5) 846-851 2012 [Refereed]

[Diagnostic examination of type 2 diabetes mellitus].

K. Nagashima; N. Inagaki

Nihon rinsho. Japanese journal of clinical medicine 70 Suppl 3 426-432 2012 [Refereed]

A case of fulminant type 1 diabetes mellitus with systemic scleroderma with double-positivity for antibodies to glutamic acid decarboxylase (gad) and insulinoma-associated antigen-2 (IA-2)

M. Sasaki; N. Harada; H. Sato; K. Toyoda; A. Hamasaki; K. Nagashima; S. Fujimoto; N. Inagaki

Journal of the Japan Diabetes Society 55(10) 781-785 2012 [Refereed]

Improvement of recurrent unstable glycemic control using continuous glucose monitoring (CGM) in a patient with diabetes complicated by insulin antibodies

T. Fukushima; N. Harada; M. Sasaki; D. Tanaka; A. Hamasaki; K. Nagashima; M. Yawata; N. Inagaki

Journal of the Japan Diabetes Society 55(12) 966-972 2012 [Refereed]

[The pathophysiology, diagnosis, and treatment for neonatal hypoglycemia].

K. Nagashima; N. Inagaki

Nihon rinsho. Japanese journal of clinical medicine 70 Suppl 5 667-670 2012 [Refereed]

[109th Scientific Meeting of the Japanese Society of Internal Medicine: educational lecture: 9. Incretin-based therapy for type 2 diabetes mellitus].

N. Inagaki

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 101(9) 2698-2705 2012 [Refereed]

Impact of endogenous and exogenous insulin on basal energy expenditure in patients with type 2 diabetes under standard treatment

K. Ikeda; S. Fujimoto; M. Goto; C. Yamada; A. Hamasaki; K. Shide; T. Kawamura; N. Inagaki

American Journal of Clinical Nutrition 94(6) 1513-1518 Dec 2011 [Refereed]

Systems analysis of GLP-1 receptor signaling in pancreatic β-cells

Y. Takeda; A. Amano; A. Noma; Y. Nakamura; S. Fujimoto; N. Inagaki

American Journal of Physiology - Cell Physiology 301(4) C792-C803 Oct 2011 [Refereed]

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice

T. Himeno; H. Kamiya; K. Naruse; N. Harada; N. Ozaki; Y. Seino; T. Shibata; M. Kondo; J. Kato; T. Okawa; A. Fukami; Y. Hamada; N. Inagaki; Y. Seino; D.J. Drucker; Y. Oiso; J. Nakamura

Diabetes 60(9) 2397-2406 Sep 2011 [Refereed]

Three-dimensional ex vivo imaging and analysis of intraportal islet transplants

H. Fujimoto; K. Toyoda; T. Okitsu; X. Liu; E. Mukai; X. Zhuang; S. Uemoto; N. Mochizuki; N. Inagaki

Transplant International 24(8) 839-844 Aug 2011 [Refereed]

Ionic mechanisms and Ca²⁺ dynamics underlying the glucose response of pancreatic β cells: A simulation study

C.Y. Cha; Y. Nakamura; Y. Himeno; J.W. Wang; S. Fujimoto; N. Inagaki; Y.E. Earm; A. Noma

Journal of General Physiology 138(1) 21-37 Jul 2011 [Refereed]

Role of mitochondrial phosphate carrier in metabolism-secretion coupling in rat insulinoma cell line INS-1

Y. Nishi; S. Fujimoto; M. Sasaki; E. Mukai; H. Sato; Y. Sato; Y. Tahara; Y. Nakamura; N. Inagaki

Biochemical Journal 435 421-430 Apr 2011 [Refereed]

GCKR mutations in Japanese families with clustered type 2 diabetes

D. Tanaka; K. Nagashima; M. Sasaki; C. Yamada; S. Funakoshi; K. Akitomo; K. Takenaka; K. Harada; A. Koizumi; N. Inagaki

Molecular Genetics and Metabolism 102(4) 453-460 Apr 2011 [Refereed]

The effect of gastric inhibitory polypeptide on intestinal glucose absorption and intestinal motility in mice

E. Ogawa; M. Hosokawa; N. Harada; S. Yamane; A. Hamasaki; K. Toyoda; S. Fujimoto; Y. Fujita; K. Fukuda; K. Tsukiyama; Y. Yamada; Y. Seino; N. Inagaki

Biochemical and Biophysical Research Communications 404(1) 115-120 Jan 2011 [Refereed]

Exendin-4 suppresses Src activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner

E. Mukai; S. Fujimoto; H. Sato; C. Oneyama; R. Kominato; Y. Sato; M. Sasaki; Y. Nishi; M. Okada; N. Inagaki

Diabetes 60(1) 218-226 Jan 2011 [Refereed]

Targeting β-cell functions in therapy for type 2 diabetes

S. Fujimoto; N. Inagaki

Journal of Diabetes Investigation 2(3) 178-179 2011 [Refereed]

Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects

N. Harada; A. Hamasaki; S. Yamane; A. Muraoka; E. Joo; K. Fujita; N. Inagaki

Journal of Diabetes Investigation 2(3) 193-199 2011 [Refereed]

Misc

Plain Text1 2 >

Gastrointestinal hormone precursors.

稲垣暢也

Progress in Endocrinology, Elsevier, Amsterdam,,81-88/, 1988 [Refereed]

cDNA cloning, gene organization and expression of GIP precursor

H. Imura; J. Takeda; N. Inagaki; H. Yano; Y. Yamada; K. Tsuji; T. Taminato; T. Mitani; Y. Seino

Diabetes 1988: proceedings of the 13th Congress of the International Diabetes Federation. ICS800 189- 192 1989 [Refereed]

c-Jun represses the human insulin promoter activity that depends on multiple cAMP response elements

N. Inagaki; T. Maekawa; T. Sudo; S. Ishii; Y. Seino; H. Imura

Proceedings of the National Academy of Sciences of the United States of America 89(3) 1045-1049 Feb 1992 [Refereed]

Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells

N. Inagaki; H. Yoshida; M. Mizuta; N. Mizuno; Y. Fujii; T. Gonoi; J.-I. Miyazaki; S. Seino

Proceedings of the National Academy of Sciences of the United States of America 91(7) 2679-2683 1994 [Refereed]

PACA/VIP receptors in pancreatic β-cells: Their roles in insulin secretion

N. Inagaki; H. Kuromi; S. Seino

Annals of the New York Academy of Sciences 805 44-53 1996 [Refereed]

Association Memberships

The Physiological Society of Japan(457) , The Japanese Biochemical Society(1772) , The Molecular Biology Society of Japan(2658) , The Japan Diabetes Society(364) , The Japanese Cancer Association(1413) , The Japanese Society of Internal Medicine(1808) , The American Diabetes Association(7) , Physiological Society of Japan(265) , Japanese Cancer Association(347)

Research Grants & Projects

Plain Text

Regulatory mechanisms of ion channels and transporters

regulatory mechanisms of neural function

molecular mechanisms of insulin secretion